Drugs / INE963
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04896632 | May 2021 → Nov 2022 | — | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05750628 | Jan 2024 → Jun 2026 overdue | Plasmodium falciparum malaria | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 2 | NCT07235020 | Jan 2024 → Jan 2025 | Plasmodium falciparum malaria | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INE 963 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04896632 ↗ |
| Modality | Small molecule | — CHEMBL5173264 ↗ |
| Route | Oral | “INE963 given orally” NCT04896632 ↗ |